GAIL ECKHARDT to Antineoplastic Agents
This is a "connection" page, showing publications GAIL ECKHARDT has written about Antineoplastic Agents.
Connection Strength
0.560
-
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol. 2013 Mar 20; 31(9):1231-8.
Score: 0.220
-
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anticancer Drugs. 2018 10; 29(9):827-838.
Score: 0.082
-
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
Score: 0.072
-
Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol Carcinog. 2017 03; 56(3):1189-1196.
Score: 0.071
-
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75.
Score: 0.062
-
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81.
Score: 0.053